BRPI0518984A2 - anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal - Google Patents

anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal

Info

Publication number
BRPI0518984A2
BRPI0518984A2 BRPI0518984-5A BRPI0518984A BRPI0518984A2 BR PI0518984 A2 BRPI0518984 A2 BR PI0518984A2 BR PI0518984 A BRPI0518984 A BR PI0518984A BR PI0518984 A2 BRPI0518984 A2 BR PI0518984A2
Authority
BR
Brazil
Prior art keywords
treatment
cell proliferation
abnormal cell
viral infections
nucleoside analogs
Prior art date
Application number
BRPI0518984-5A
Other languages
English (en)
Inventor
Dennis C Liotta
Shuli Mao
Michael Hager
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BRPI0518984A2 publication Critical patent/BRPI0518984A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ANÁLOGOS DE NUCLEOSÍDEO CICLOBUTIL SUBSTITUÍDOS EM 2' E 3'PARA TRATAMENTO DE INFECÇOES VIRAIS E PROLIFERAÇAO CELULAR ANORMAL. São fornecidos nucleosídeos ciclobutil e métodos para seu uso no tratamento de infecções que incluem infecções por Retroviridae (incluindo HIV), Hepadnaviridae (incluindo HBV) ou Flavivirídae (incluindo BVDV e HCV), ou de condições relacionadas à proliferação celular anormal, em um hospedeiro, incluindo animais, e especialmente seres humanos.
BRPI0518984-5A 2004-12-10 2005-12-08 anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal BRPI0518984A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63487504P 2004-12-10 2004-12-10
PCT/US2005/044709 WO2006063281A2 (en) 2004-12-10 2005-12-08 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation

Publications (1)

Publication Number Publication Date
BRPI0518984A2 true BRPI0518984A2 (pt) 2008-12-16

Family

ID=36578634

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518984-5A BRPI0518984A2 (pt) 2004-12-10 2005-12-08 anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal

Country Status (9)

Country Link
US (2) US7495006B2 (pt)
EP (1) EP1828145A4 (pt)
JP (1) JP2008523098A (pt)
CN (1) CN101115725A (pt)
AU (1) AU2005313912A1 (pt)
BR (1) BRPI0518984A2 (pt)
CA (1) CA2590115A1 (pt)
MX (1) MX2007006961A (pt)
WO (1) WO2006063281A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072329A1 (en) * 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
DK2512474T3 (en) 2009-12-16 2014-12-01 Pfizer N-linked hydroxamic acid derivatives which can be used as antibacterial agents
MA34963B1 (fr) 2011-03-07 2014-03-01 Pfizer Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
MY171577A (en) 2011-12-20 2019-10-21 Hoffmann La Roche 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
HK1200835A1 (en) 2011-12-20 2015-08-14 Riboscience Llc 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
EP2996695B1 (en) 2013-05-16 2022-04-13 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives
AU2014272055A1 (en) 2013-05-16 2015-12-24 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
SG11201703992YA (en) 2014-11-19 2017-06-29 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN110049767B (zh) * 2016-10-03 2023-04-04 艾库斯生物科学有限公司 腺苷5′-核苷酸酶的抑制剂
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
EP3684374B1 (en) 2017-09-21 2025-07-30 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법
CN119431343B (zh) * 2024-11-04 2026-04-10 河南大学 一种m6A去甲基化酶ALKBH1小分子抑制剂、合成方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855466A (en) * 1987-12-28 1989-08-08 E. R. Squibb & Sons, Inc. Purinyl cyclobutanes
EP0330992A3 (en) * 1988-02-29 1991-11-06 Nippon Kayaku Kabushiki Kaisha Novel cyclobutane derivatives, processes for their preparation and pharmaceutical compositions comprising them
US5185459A (en) * 1988-03-30 1993-02-09 E. R. Squibb & Sons Inc. Bis protected (hydroxymethyl)cyclobutanols
US5130462A (en) * 1988-03-30 1992-07-14 E. R. Squibb & Sons, Inc. Cyclobutane derivatives
US5126345A (en) * 1988-03-30 1992-06-30 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl triazolopyrimidines
IL92096A0 (en) * 1988-10-25 1990-07-12 Abbott Lab Carboxylic nucleoside analogs
US4918075A (en) * 1988-12-20 1990-04-17 E. R. Squibb & Sons, Inc. Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents
US5324730A (en) * 1990-05-24 1994-06-28 Nippon Kayaku Kabushiki Kaisha Phenoxyphosphoryloxymethyl cyclobutyl purines
CA2042931A1 (en) * 1990-05-24 1991-11-25 Robert Zahler Fluorinated bis (hydroxymethyl) cyclobutyl purines and pyrimidines
US5166397A (en) * 1990-09-20 1992-11-24 Nippon Kayaku Kabushiki Kaisha Process for producing optically active cyclobutylamines
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
MX2007006961A (es) * 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.

Also Published As

Publication number Publication date
US7495006B2 (en) 2009-02-24
MX2007006961A (es) 2007-10-04
EP1828145A4 (en) 2009-08-19
WO2006063281A3 (en) 2006-10-12
US20060223835A1 (en) 2006-10-05
EP1828145A2 (en) 2007-09-05
US8114994B2 (en) 2012-02-14
AU2005313912A1 (en) 2006-06-15
JP2008523098A (ja) 2008-07-03
CA2590115A1 (en) 2006-06-15
WO2006063281A2 (en) 2006-06-15
CN101115725A (zh) 2008-01-30
US20090149416A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
BRPI0518984A2 (pt) anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal
DK2251015T3 (da) Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
Tonelli et al. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives
NZ543867A (en) Modified fluorinated nucleoside analogues
PA8588501A1 (es) Derivados antivirales de nucleósidos
NO20033289L (no) Nukleosidderivater som inhibitorer for RNA-avhengig RNA- viruspolymerase
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
TW200500373A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312278A (pt) éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
GT199900166A (es) Compuesto quìmico adecuado para usar como agente antiviral.-
WO2003105770A3 (en) Carbocyclic nucleoside analogs as rna-antivirals
PE20030256A1 (es) Nucleosidos 4 sustituidos como inhibidores de la replicacion del arn del virus de la hepatitis c
BR0307712A (pt) Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
RS20120201A3 (en) Methods and compositions for hepatitis c virus treatment
EP1653976A4 (en) ANTI-VIRAL NUCLEOSIDE ANALOGUE AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS, IN PARTICULAR HIV INFECTIONS
ATE475660T1 (de) Antivirale verbindungen
ID27290A (id) Penggunaan senyawa 1,5-dideoksi-1,5-imino-d-glusitol tersubstitusi-n pada pengobatan infeksi virus hepatitis
NO20034878D0 (no) Antivirale forbindelser
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
BR0016163A (pt) Tratamento de infecções virais que usa levovirin(r)
PA8590801A1 (es) Derivados de nucleosido antivirales
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
WO2004062575A3 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.